Progress in Oncology 2002


Book Description

The second volume in the annual series, Progress In Oncology 2002 highlights progress in the basic and clinical aspects of oncology and is reviewed by leaders in the field. Comprehensive reviews on important advances in the previous year are selected to help cancer research scientists and oncologists stay up-to-date with high impact progress across all disciplines in oncology.




Progress in Oncology 2002 and 2001


Book Description

Buy Progress in Oncology 2002 and 2001 together and save! Each year this volume will highlight progress in the basic and clinical aspects of oncology reviewed by leaders in the field. Comprehensive reviews on important advances in the previous year will be selected to help cancer research scientists and oncologists stay up-to-date with high impact progress across all disciplines in oncology.







Therapeutic Progress in Oncology


Book Description

The combined effects of population growth and aging have led to an increase in the number of cancers. Preventing, diagnosing, treating and curing cancer are therefore, more than ever, imperatives facing medicine – especially to continue the decrease in cancers' mortality rates and to improve the quality of survival. Over time, the “classic” modes of treatment (surgery, external beam radiotherapy, chemotherapy) have become more refined and efficient. From the beginning of this century, new therapeutic options have been developed: targeted cancer therapy, targeted radionuclide therapy and immunologic therapies based on monoclonal antibodies, cellular therapy and vaccinations. Artificial intelligence and machine learning are also being introduced to the field of oncology. Starting with the basic scientific principles relevant to oncology, this book explains and makes these concepts and innovations accessible to a wide audience – especially in the interest of patients. It also contributes to the oncological field of 4P medicine – with 4P standing for predictive, preventive, personalized and participative.




Cancer Care for the Whole Patient


Book Description

Cancer care today often provides state-of-the-science biomedical treatment, but fails to address the psychological and social (psychosocial) problems associated with the illness. This failure can compromise the effectiveness of health care and thereby adversely affect the health of cancer patients. Psychological and social problems created or exacerbated by cancer-including depression and other emotional problems; lack of information or skills needed to manage the illness; lack of transportation or other resources; and disruptions in work, school, and family life-cause additional suffering, weaken adherence to prescribed treatments, and threaten patients' return to health. Today, it is not possible to deliver high-quality cancer care without using existing approaches, tools, and resources to address patients' psychosocial health needs. All patients with cancer and their families should expect and receive cancer care that ensures the provision of appropriate psychosocial health services. Cancer Care for the Whole Patient recommends actions that oncology providers, health policy makers, educators, health insurers, health planners, researchers and research sponsors, and consumer advocates should undertake to ensure that this standard is met.




Progress in Oncology 2003


Book Description

The third volume in this outstanding series of annual updates in oncology, Progress in Oncology 2003 addresses nineteen of the most important “hot topics” in the field. Under the careful direction of Drs. DeVita, Hellman, and Rosenberg, each annual volume in this exciting series presents concise summaries of the state of the art in cancer basic science and clinical application, written by 34 of the top researchers and clinicians in the world. As with all the volumes in the series, PIO 2003 covers critical issues in clinical cancer care and research in a scholarly though readable style. Chapters on advances in treatment and diagnosis, including radioimmunotherapy, molecular markers, radiolabeled octreotide, and microarray analysis review the state of the art in these emerging fields. Top experts provide timely overviews of mammographic screening recommendations and current therapy for pancreatic tumors. In special section, world-class authorities debate the use of Alpha Interferon in melanoma treatment. These and other rigorously referenced chapters make PIO 2003 an indispensable new oncology resource.




Progress in Anti-Cancer Chemotherapy


Book Description

This is the third volume of our series Progress in Anti-Cancer Chemo therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu tions from some of the world's best known leaders in both basic and clin ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib itors in research and the therapeutic ramifications.




Progress in Oncology 2004


Book Description

The fourth volume in this outstanding series of annual updates in oncology, Progress in Oncology 2004 addresses fifteen of the most important "hot topics" in the field. Under the careful direction of Drs. DeVita, Hellman, and Rosenberg, each volume in this exciting series presents concise summaries of the state of the art in cancer basic science and clinical application, written by 15 of the top researchers and clinicians in the world.As with all the volumes in the series, PIO 2004 covers critical issues in clinical cancer care and research in a scholarly though readable style. Chapters on advances in treatment and diagnosis, including DNA microarrays, growth factor receptors, new applications of thalidomide, and allografting in NHL review the state of the art in these emerging fields. Top experts provide timely overviews of focused ultrasound therapy, hormone therapy for prostate cancer, and CHOP and rituxin for DLCL. In a special surgery section, world-class authorities discuss approaches to rectal cancer. These and other rigorously referenced chapters make PIO 2004 an indispensable new oncology resource.